Zimmer Holdings, Inc. has gotten its hands on breakthrough technology in biomimetic calcium phosphate, which mimics the chemical and structural features of human bone, promotes natural bone regeneration.
On October 1, 2014, the company announced it was acquiring Cambridge, Massachusetts-based ETEX Holdings, Incorporated. ETEX was founded in 1989 by Harvard Dental School researcher Dosuk Lee.
According to our friends at Mass Device, ETEX has not disclosed outside funding since 2005, when it booked nearly $5 million. That year, an arbitrator ordered Medtronic, Inc. to pay ETEX $50.2 million, ruling that Medtronic improperly canceled a deal following an assessment of a bone graft product ETEX had been developing.
ETEX Products
The financial terms of the transaction were not disclosed. According to a company press release, the acquisition “enhances Zimmer’s Biologics portfolio of differentiated treatments through the addition of ETEX’s Beta-bsm (injectable), CarriGen, EquivaBone (including DBM[demineralized bone matrix]), and Gamma-bsm (putty) bone void filler products.”
Joseph Cucolo, president of Zimmer Americas, said Zimmer is committed to developing the most comprehensive range of biologic therapies in musculoskeletal care. As proof, he cites intervention solutions like Gel-One cross-linked hyaluronate and joint preservation solutions like Zimmer Knee Creations Subchondroplasty Procedure, along with Zimmer’s Chondrofix Osteochondral Allograft and Denovo NT Natural Tissue Graft personalized cartilage solutions.
Joint Preservation Business
More and more it looks like Zimmer is in the joint preservation business, as the former company’s Chief Science Office Cheryl Blanchard, Ph.D. once told us. “ETEX’s innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease, ” added Cucolo.
It was reported in July 2010 that ETEX signed a distribution deal with Stryker Corp. for a pair of its private-label bone graft substitute products. The non-exclusive distribution deal was for Stryker’s spine division to market and sell ETEX’s Bio MatrX Structure and Bio MatrX Generate products. Both products incorporated ETEX’s nanocrystalline calcium phosphate bone putty.
I have cts and hip and shoulder bursitis vascular necrosis and would like to know if this product is available for my joint problems and if so please direct me to where I can go to receive this .
ETEX, only problem in the past has been price, the product works well, mixed with BMP the results have been phenomenal.